WALTHAM, Mass., United States – May 5, 2026
Viridian Therapeutics Inc. has announced positive topline results from its Phase 3 REVEAL-2 clinical trial evaluating elegrobart in patients with chronic thyroid eye disease (TED), demonstrating highly statistically significant efficacy across primary and key secondary endpoints. The study confirmed that both Q4W and Q8W dosing regimens achieved strong proptosis responder rates of 50% and 54%, respectively, compared to 15% for placebo (p < 0.0001), reinforcing elegrobart’s potential as a best-in-class anti-IGF-1R therapy. With these results, the company remains on track for a Biologics License Application (BLA) submission to the U.S. Food and Drug Administration in Q1 2027, positioning elegrobart as a potential first subcutaneous, at-home autoinjector treatment for TED.
Strong Phase 3 Efficacy Across Key Endpoints
The REVEAL-2 trial, which enrolled 204 patients, successfully met its primary endpoint for both FDA and EMA, demonstrating robust clinical benefit in reducing proptosis, a key marker of disease severity in TED. Patients receiving elegrobart showed mean reductions of up to −2.1 mm in eye protrusion, significantly outperforming placebo. In addition, the Q4W dosing arm achieved a statistically significant 61% diplopia responder rate, compared to 38% with placebo (p = 0.0118), indicating meaningful improvement in double vision symptoms, which are among the most disabling aspects of the disease. Importantly, efficacy outcomes were consistent across patient subgroups, including varying baseline disease activity, highlighting the therapy’s broad clinical applicability in chronic TED.
Favorable Safety Profile and High Treatment Completion
Viridian Therapeutics Inc. reported that elegrobart was generally well tolerated, with a safety profile consistent with earlier studies, including REVEAL-1, and aligned with expectations for the anti-IGF-1R class. The majority of adverse events were mild in severity, with low rates of hearing impairment observed across treatment groups. Notably, 91% of patients completed the full course of therapy, and there were no treatment-related serious adverse events, reinforcing confidence in the drug’s clinical safety and patient adherence potential. This combination of efficacy, safety, and tolerability is critical in chronic diseases where long-term treatment is often required.
Advertisement
Strategic Positioning in a High-Value TED Market
The success of REVEAL-2 marks the second pivotal Phase 3 trial success for elegrobart, following positive results from REVEAL-1, establishing a strong foundation for regulatory approval and commercialization. Viridian Therapeutics Inc. is strategically positioning elegrobart alongside its lead program veligrotug, which is currently under Priority Review with a PDUFA target date of June 30, 2026, creating a dual-asset portfolio targeting both active and chronic TED.
The potential launch of an at-home autoinjector therapy represents a major shift from existing treatment paradigms, which often require intravenous administration in clinical settings, thereby improving patient convenience, adherence, and market adoption. With TED representing a large and underserved autoimmune market, these results significantly strengthen Viridian’s competitive position and highlight a broader industry trend toward patient-friendly biologic therapies with simplified delivery models.
Source: Viridian Therapeutics press release
